[CPRX] Catalyst Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 1.09 Change: 0 (0%)
Ext. hours: Change: 0 (0%)

chart CPRX

Refresh chart

Strongest Trends Summary For CPRX

CPRX is in the medium-term up 109% in 2 years. In the long-term up 425% in 6 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Catalyst Pharmaceutical Partners, Inc. operates as development-stage specialty pharmaceutical company. The company focuses on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases and disorders. Its principal product candidate is Firdapse, a proprietary form of amifampridine phosphate, which is in Phase III clinical trial for the treatment of Lambert-Eaton Myasthenic Syndrome. The company also develops CPP-115, a vigabatrin analog to treat infantile spasms and epilepsy, as well as other neurological conditions associated with reduced GABAergic signaling, such as post-traumatic stress disorder and Tourette syndrome. Catalyst Pharmaceutical Partners, Inc. has strategic collaboration agreement with BioMarin. The company was founded in 2002 and is based in Coral Gables, Florida.

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-22.5% ROE-25.68% ROI
Current Ratio12.99 Quick Ratio Long Term Debt/Equity Debt Ratio0.09
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities36.06 M Cash From Investing Activities-40 K Cash From Operating Activities-3.79 M Gross Profit
Net Profit-5.41 M Operating Profit-4.29 M Total Assets76.05 M Total Current Assets75.97 M
Total Current Liabilities5.85 M Total Debt Total Liabilities9.43 M Total Revenue
Technical Data
High 52 week6.11 Low 52 week1.92 Last close5.03 Last change-0.98%
RSI75.81 Average true range0.28 Beta0.62 Volume310.27 K
Simple moving average 20 days7.3% Simple moving average 50 days22.15% Simple moving average 200 days42.18%
Performance Data
Performance Week-0.59% Performance Month23.59% Performance Quart60.19% Performance Half103.64%
Performance Year71.67% Performance Year-to-date161.98% Volatility daily2.68% Volatility weekly6%
Volatility monthly12.3% Volatility yearly42.6% Relative Volume298.06% Average Volume1.66 M
New High New Low

News

2020-05-17 08:31:39 | What Does The Future Hold For Catalyst Pharmaceuticals, Inc. NASDAQ:CPRX? These Analysts Have Been Cutting Their Estimates

2020-05-14 08:18:51 | Catalyst Pharmaceuticals, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

2020-05-11 19:25:11 | Catalyst Pharmaceutical CPRX Surpasses Q1 Earnings Estimates

2020-05-11 16:17:10 | Catalyst Pharmaceuticals Announces First Quarter 2020 Financial Results and Provides Corporate Update

2020-05-04 08:03:10 | Catalyst Pharmaceuticals to Hold First Quarter 2020 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, May 12th, 2020

2020-04-29 10:02:57 | Healthcare Pro Steven Boyd Is Gobbling Up These 3 Stocks

2020-04-29 05:33:00 | Is Catalyst Pharmaceuticals a Buy?

2020-04-15 11:30:03 | Catalyst CPRX Up 52.1% Since Last Earnings Report: Can It Continue?

2020-04-08 06:00:10 | Catalyst Pharmaceuticals Provides Update on Impact of COVID-19 Pandemic on its Business Activities

2020-03-17 19:21:09 | Edited Transcript of CPRX earnings conference call or presentation 17-Mar-20 12:30pm GMT

2020-03-17 06:30:00 | Catalyst Pharmaceuticals, Inc. to Host Earnings Call

2020-03-16 17:26:58 | Catalyst Pharmaceuticals Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Corporate Update

2020-03-10 08:03:10 | Catalyst Pharmaceuticals to Hold Fourth Quarter and Year-End Financial Results and Corporate Update Conference Call and Webcast on Tuesday, March 17th, 2020

2020-03-09 12:30:04 | Catalyst Pharmaceutical CPRX Earnings Expected to Grow: What to Know Ahead of Q4 Release

2020-02-27 08:03:10 | Catalyst Pharmaceuticals Announces Support of Rare Disease Day 2020

2020-02-26 08:03:10 | Catalyst Pharmaceuticals to Present at the Cowen 40th Annual Health Care Conference

2020-02-24 09:42:15 | Based On Its ROE, Is Catalyst Pharmaceuticals, Inc. NASDAQ:CPRX A High Quality Stock?

2020-02-06 08:03:10 | Catalyst Pharmaceuticals to Present at the 22nd Annual BIO CEO & Investor Conference

2020-02-04 08:02:10 | Catalyst Pharmaceuticals Appoints David Ailinger as Vice President, Business Development

2020-01-15 08:58:01 | Implied Volatility Surging for Catalyst CPRX Stock Options

2020-01-07 09:17:02 | Catalyst Gives Preliminary Firdapse Estimates & Other Updates

2020-01-06 08:03:10 | Catalyst Pharmaceuticals Pre-Announces Estimated Firdapse® Revenues and Provides Updates on Advancement of Clinical Development Programs

2019-12-24 06:33:13 | Is Catalyst Pharmaceuticals, Inc. NASDAQ:CPRX Trading At A 44% Discount?

2019-12-13 14:45:19 | Is Catalyst Pharmaceuticals, Inc. CPRX A Good Stock To Buy?

2019-12-12 11:30:04 | Why Is Catalyst CPRX Down 5.3% Since Last Earnings Report?

2019-12-04 20:35:43 | Edited Transcript of CPRX earnings conference call or presentation 13-Nov-19 1:30pm GMT

2019-11-29 09:39:02 | Catalyst Focuses on Firdapse Label Expansion Amid Competition

2019-11-26 08:03:10 | Catalyst Pharmaceuticals to Participate in the Piper Jaffray 31st Annual Healthcare Conference

2019-11-16 08:15:00 | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Catalyst Pharmaceuticals, Inc. - CPRX

2019-11-13 14:05:00 | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Catalyst Pharmaceuticals, Inc. - CPRX

2019-11-13 09:05:02 | Catalyst's CPRX Q3 Earnings Beat Estimates, Sales Miss

2019-11-12 18:26:11 | Catalyst Pharmaceutical CPRX Beats Q3 Earnings Estimates

2019-11-12 16:39:12 | Catalyst Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update

2019-11-11 17:21:47 | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Catalyst Pharmaceuticals, Inc. - CPRX

2019-11-08 10:33:32 | 3 ‘Strong Buy’ Stocks to Buy on Weakness

2019-11-07 18:15:00 | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Catalyst Pharmaceuticals, Inc. - CPRX

2019-11-01 12:32:09 | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Catalyst Pharmaceuticals, Inc. - CPRX

2019-10-31 10:45:00 | Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Catalyst Pharmaceuticals, Inc. CPRX

2019-10-31 08:03:05 | Catalyst Pharmaceuticals to Hold Third Quarter 2019 Financial Results Conference Call and Webcast on Wednesday, November 13th, 2019

2019-10-30 06:03:05 | Catalyst Pharmaceuticals Announces Top-Line Results of CMS-001, a Phase 3 Trial of Firdapse® Amifampridine Phosphate in Patients with Congenital Myasthenic Syndromes CMS

2019-10-29 15:16:07 | Investors Can Find Strong Stocks with our First Profit Screen

2019-10-29 09:46:01 | Catalyst Pharma CPRX to Post Q3 Earnings: What's in Store?

2019-10-25 08:38:43 | Did The Underlying Business Drive Catalyst Pharmaceuticals's NASDAQ:CPRX Lovely 416% Share Price Gain?

2019-10-19 21:56:58 | Top Insider Buys Highlight for the Week of Oct. 18

2019-10-01 15:06:07 | Learn How to Find Top-Ranked 'Cheap' Stocks Under $10 with this Screener

2019-09-25 08:02:00 | Catalyst Pharmaceuticals to Participate in the 2019 Cantor Global Healthcare Conference

2019-09-23 14:55:00 | Catalyst Pharmaceuticals, Inc. Comments on Trading in its Common Stock and on its Capital Resources

2019-09-19 10:37:31 | Should You Wait Before Investing In Catalyst Pharmaceuticals, Inc. NASDAQ:CPRX?

2019-09-18 09:31:01 | Buy These 7 Small Drugmakers to Boost Your Portfolio's Health

2019-09-13 10:00:02 | Catalyst Pharmaceutical CPRX is a Great Momentum Stock: Should You Buy?